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OVERLINE 
Achieving Global Targets for  
Antimicrobial Resistance 
Insert Deck Here 
By Ramanan Laxminarayan1, Devi Sridhar2, Martin Blaser3, Minggui Wang4, Mark Woolhouse5 Woolhouse2*  
After decades of neglect, antimicrobial re-
sistance (AMR) has captured the attention 
and concern of the public health community 
and global leaders. In September 2016, a 
high-level meeting of the United Nations 
General Assembly (UNGA) will discuss how 
countries can cooperate to preserve global 
access to effective antimicrobials. This will 
be only the third health issue (and the first 
One Health issue, integrating human, animal 
and environmental health) to bring together 
heads of state at the UNGA. This is a rare 
opportunity to set a global agenda to com-
bat the crisis. We believe that (i) setting tar-
gets for reducing drug resistant infections, 
(ii) adequate financing for global action, and 
(iii) defining the global health architecture 
to address AMR, should be key elements of a 
UN plan.  
The cost of antibiotic treatment and 
mortality due to resistance is increasing 
worldwide (2). The greatest burden occurs 
in low- and middle-income countries 
(LMICs), especially among the young: an es-
timated 214,000 neonatal sepsis deaths are 
attributable to resistant pathogens each 
year (7). But high-income countries are not 
immune: an estimated 23,000 people in the 
United States and 25,000 in Europe die each 
year from resistant pathogens (2,7).  
That said, lack of access and delayed ac-
cess to antibiotics kill more people than 
AMR. The challenge of expanding appropri-
ate access to antimicrobials, while restrict-
ing inappropriate access, requires new ap-
proaches to financing and delivering 
healthcare. A One Health perspective can 
address connections between antimicrobial 
use and resistance in humans, animals and 
the wider environment. 
 
Targets and Surveillance  
Use of antibiotics is the most important 
driver of selection for resistance and loss of 
effectiveness. Use is increasing globally, 
driven by rising incomes and increasing ac-
cess. Antibiotic use varies greatly in human 
and animal sectors across countries, de-
pending on prevailing medical, veterinary 
and regulatory practices.  
We propose that no country consume 
more than the current median global level 
(22 standard units per capita per year). We 
estimate that this would lower overall use 
by 21% globally (based on (8); see supple-
mental material (SM)). Reducing use is ac-
complished by improving public health and 
sanitation. In low-income countries, antibi-
otics are used to compensate for the lack of 
public health infrastructure (e.g., vaccina-
tion coverage, infection control). A target 
linked to UN Sustainable Development Goals 
3 (on health) and 6 (on water and sanita-
tion) that commits nations to improving 
public health would reduce reliance on anti-
biotics.  
Further reductions could be achieved 
through public campaigns, aimed at physi-
cians and patients, to discourage inappro-
priate antibiotic use (9), particularly in re-
sponse to seasonal influenza (8). Though 
LMICs face a higher burden of infectious 
disease, per capita consumption of antimi-
crobials in most LMICs is well below our 
target level. Thus, meeting this target need 
not compromise legitimate uses.   
There is significant potential for reduc-
ing consumption in the animal sector. We 
propose complete global phase out of use of 
antimicrobial growth promoters; five years 
would be appropriate given the urgency of 
the problem. This could avert much of the 
projected 67% increase in farm animal use 
between 2010 and 2030 (8). Though this 
would incur some cost to agricultural sec-
tors, even in China (the largest consumer of 
antibiotics in agriculture), that cost is likely 
on the order of $3 billion a year,to be a small 
fraction of the country’s burden of AMR 
(10).  Moreover, Tthe costs of improving bi-
osafety and biosecurity in farming opera-
tions to phase out antimicrobial growth 
promoters would be largely offset by lower-
ing risk of infection and cost of antimicrobi-
als. We envision a process similar to that in 
the EU where there was declared intent to 
phase out sub-therapeutic use followed by 
regulatory changes to make the transition.it 
happen.  Globaly, This this would happen-
could work through a multilateral process, 
as with global movements to phase out, e.g., 
asbestos or chlorofluorocarbons.   
National-level rRestrictions on antibiotic 
effluents from pharmaceutical manufactur-
ing, agricultural operations and hospital 
waste that end up in waterways and con-
tribute to the buildup of resistance genes in 
the soil and water are an urgent priority.  
While setting tTargets for reductions in 
antibiotic consumption is importantshould 
be accompanied by, outcome-based targets 
are critical to assess progress against the ul-
timate goal of reducing drug-resistant infec-
tions. We propose targets be set to reduce 
levels of a drug resistance index (e.g., the 
proportion of infections that are resistant), 
based on weighted-averrage of resistance of 
the eight World Health Organization (WHO) 
priority pathogens to first line antibiotics, 
nationally, regionally and globally within 5 
years (10a). Reductions should be relative 
to 2016 levels, based on the eight World 
Health Organization (WHO) priority patho-
gens. We do not specify the scale of reduc-
tion – the immediate priority is to prevent 
increases – but recommend a review after 5 
yearsin 2021 to consider more stringent 
targets. The weighting given to each drug, 
and strategies chosen , would reflect usage 
health system context and priorities of indi-
vidual countries.  
Existing surveillance programs for AMR 
can contribute to target monitoring at the 
national level (11), including the Global An-
timicrobial Resistance Surveillance System, 
and ResistanceMap (12). Surveillance 
should involve the livestock sector and the 
wider environment, and track access and 
use, and indicators such as water, sanitation, 
and vaccination coverage. Data on AMR 
must be translated into epidemiologically 
sound estimates of public health burden, 
which requires information on treatment 
rates and failures (7) not routinely collected 
at present. 
Surveillance cannot be the sole respon-
sibility of individual countries; surveillance 
is a global good and should be financed ac-
cordingly. Initiatives such as the Fleming 
Fund and the Global Health Security Agenda 
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provide opportunities to strengthen surveil-
lance in countries with poor public health 
architecture. Not all surveillance elements 
need to be replicated at a national level; in-
tegrating local activities into multi-national 
networks may be more efficient, with ap-
propriate structures for data sharing, analy-
sis and communication. 
 
Global financing  
Substantial funds have been committed 
in the U.S. and Europe to tackle AMR, but 
success will be limited without global scale 
investments. The need to incentivize devel-
opment of new vaccines, diagnostics, novel 
therapies and stewardship methods, as well 
as traditional antibiotics to ensure availabil-
ity of the “antibiotic umbrella” has been 
widely recognized (13). Vaccines, for ani-
mals and humans, face high development 
costs and uncertain markets; however, the 
GAVI Vaccine Alliance financing mechanism 
has been successful in bringing new vac-
cines into wide use.  
Development and deployment of diag-
nostics is more difficult. Knowledge of the 
underlying pathogen and its drug sensitivity 
would improve antibiotic use, but new di-
agnostics are needed. Diagnostics must be 
rapid and sufficiently inexpensive if they are 
to be used prior to the decision to begin an-
tibiotic treatment. The Longitude, Horizon 
and NIAID prizes for innovative diagnostics 
stipulate that winners demonstrate the fea-
sibility of deploying globally.  
Novel alternatives to traditional antibi-
otics are needed. Multiple non-compound 
approaches that target bacteria or the host 
have been proposed (14). Antibiotics can in-
teract to synergize, antagonize, or suppress 
each other’s effects (15), modifying the evo-
lution of resistance.  
Financial stimuli for antibiotic develop-
ment must address the lack of incentives for 
appropriate use (16) and should enable sus-
tainable access, when clinically appropriate. 
There are proposals for delinkage where 
the pharmaceutical company would have no 
incentive to oversell the antibiotic (e.g., 
EXAMPLE AND REFERENCE). Initiatives to 
improve the development pipeline for new 
antibiotics have been proposed and some 
are being implemented (e.g. the Generating 
Antibiotics Incentives Now in the U.S. (17) 
and the Innovative Medicines Initiative in 
Europe (18)) but cannot be long term solu-
tions because resistance develops quickly to 
new antibiotics. Initiatives like the Afforda-
ble Medicines Facility-malaria, that aimed to 
conserve the effectiveness of antimalarial 
drugs, involved a high-level subsidy (aimed 
at manufacturers, not retailers) and were 
found to be moderately successful at in-
creasing sales of quality-assured, artemis-
inin combinations and reducing the use of 
monotherapies that contribute to drug re-
sistance (19,20). Scaling from the size of re-
sponse relative to GDP in the EU and US 
(which allocates ~$1bn annually to AMR), 
we anticipate a global fund of at least $5 bil-
lion annually will be needed.  
 
Global architecture 
The global response to HIV/AIDS, effec-
tive in curtailing that epidemic, was acceler-
ated by the 2001 UNGA on HIV/AIDS (21). A 
clear set of actions tied to targets, financing, 
institutional commitment to cross-sectoral 
coordination at the national level, interna-
tional monitoring and accountability, and 
civil society participation should also now 
be reflected in a UNGA plan for AMR. A 
global architecture must transcend the indi-
vidual animal and human domains (22). 
Proposed approaches include ones similar 
to the Intergovernmental Panel on Climate 
Change, or the Montreal Protocol (23).  
The current tripartite arrangement be-
tween WHO, the Food and Agricultural Or-
ganization (FAO), and World Organization 
for Animal Health (OIE) offers promise but 
is unlikely to be sustainable given their oth-
er priorities. We recommend a new High-
level Coordinating Mechanism (HLCM) un-
der the UN Secretary General because: (i) 
access to effective antimicrobials transcends 
the remit of WHO, involving animal health 
and the environment; (ii) non-state actors 
play an important role; (iii) significant new 
funding is needed for research and devel-
opment.  
The HLCM consisting of WHO, FAO, OIE, 
the World Bank, relevant UN agencies and 
other international organizations, major 
multisectoral stakeholders and global ex-
perts, and reporting to the UN Secretary 
General should coordinate support for de-
velopment, implementation and monitoring 
of national plans and relevant actions. It can 
raise awareness and financing if the leader-
ship is given seniority within the UN system. 
A new entity HLCM would allow a more in-
clusive governing body (e.g. with non-state 
actor voting rights) as well as substantial 
engagement with civil society, patient 
groups, and the private sector.  
Financing would likely come through a 
replenishment process, such as used by the 
Global Fund and the GAVI Alliance through 
World Bank Trust Funds (25); an organiza-
tion solicits multi-year donor commitments 
on a regular schedule (e.g., every three 
years), rather than every year. Buy-in of 
countries across the world, particularly G77 
members, as well as funders such as the Bill 
& Melinda Gates Foundation would be es-
sential. 
Antibiotic resistance threatens to erase 
decades of progress in medicine, food secu-
rity, and public health. Global collective ac-
tion rooted in national responses is neces-
sary. The UNGA high level meeting on AMR 
could help shift world opinion, build con-
sensus around core feasible goals, and inte-
grate solutions into policy approaches by 
UN member states, international organiza-
tions, and philanthropies. 
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